Global Active Pharmaceutical Ingredients (API) CDMO Market Research Report 2024, Forecast to 2032
Report Overview
Active Pharmaceutical Ingredient (API) Contract Development and Manufacturing Organization (CDMO) provides services related to the development, manufacturing, and supply of active pharmaceutical ingredients used in the formulation of pharmaceutical products. API CDMOs play a crucial role in the pharmaceutical industry by assisting pharmaceutical companies in bringing their drug products to market efficiently and cost-effectively.
The global Active Pharmaceutical Ingredients (API) CDMO market size was estimated at USD 53870 million in 2023 and is projected to reach USD 109494.50 million by 2032, exhibiting a CAGR of 8.20% during the forecast period.
North America Active Pharmaceutical Ingredients (API) CDMO market size was estimated at USD 16079.53 million in 2023, at a CAGR of 7.03% during the forecast period of 2024 through 2032.
This report provides a deep insight into the global Active Pharmaceutical Ingredients (API) CDMO market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Active Pharmaceutical Ingredients (API) CDMO Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Active Pharmaceutical Ingredients (API) CDMO market in any manner.
Global Active Pharmaceutical Ingredients (API) CDMO Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Recipharm
Cambrex Corporation
Patheon (Thermo Fisher Scientific)
CordenPharma
Lonza
Siegfried
Catalent
Boehringer Ingelheim
Piramal Group
AbbVie
SGS Quay Pharmaceuticals
Aenova Group
Curia
Sterling Pharma Solutions
Eurofins CDMO
Market Segmentation (by Type)
Macromolecular API
Small Molecule API
Market Segmentation (by Application)
Clinical
Commercial
Others
Geographic Segmentation
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Active Pharmaceutical Ingredients (API) CDMO Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region from the consumer side and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of Active Pharmaceutical Ingredients (API) CDMO, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region during the forecast period.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment during the forecast period.
Chapter 13 is the main points and conclusions of the report.
Active Pharmaceutical Ingredient (API) Contract Development and Manufacturing Organization (CDMO) provides services related to the development, manufacturing, and supply of active pharmaceutical ingredients used in the formulation of pharmaceutical products. API CDMOs play a crucial role in the pharmaceutical industry by assisting pharmaceutical companies in bringing their drug products to market efficiently and cost-effectively.
The global Active Pharmaceutical Ingredients (API) CDMO market size was estimated at USD 53870 million in 2023 and is projected to reach USD 109494.50 million by 2032, exhibiting a CAGR of 8.20% during the forecast period.
North America Active Pharmaceutical Ingredients (API) CDMO market size was estimated at USD 16079.53 million in 2023, at a CAGR of 7.03% during the forecast period of 2024 through 2032.
This report provides a deep insight into the global Active Pharmaceutical Ingredients (API) CDMO market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Active Pharmaceutical Ingredients (API) CDMO Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Active Pharmaceutical Ingredients (API) CDMO market in any manner.
Global Active Pharmaceutical Ingredients (API) CDMO Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Recipharm
Cambrex Corporation
Patheon (Thermo Fisher Scientific)
CordenPharma
Lonza
Siegfried
Catalent
Boehringer Ingelheim
Piramal Group
AbbVie
SGS Quay Pharmaceuticals
Aenova Group
Curia
Sterling Pharma Solutions
Eurofins CDMO
Market Segmentation (by Type)
Macromolecular API
Small Molecule API
Market Segmentation (by Application)
Clinical
Commercial
Others
Geographic Segmentation
- North America (USA, Canada, Mexico)
- Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
- South America (Brazil, Argentina, Columbia, Rest of South America)
- The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Active Pharmaceutical Ingredients (API) CDMO Market
- Overview of the regional outlook of the Active Pharmaceutical Ingredients (API) CDMO Market:
- Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
- This enables you to anticipate market changes to remain ahead of your competitors
- You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
- The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
- Provision of market value data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
- Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
- Provides insight into the market through Value Chain
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- 6-month post-sales analyst support
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Active Pharmaceutical Ingredients (API) CDMO Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region from the consumer side and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of Active Pharmaceutical Ingredients (API) CDMO, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region during the forecast period.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment during the forecast period.
Chapter 13 is the main points and conclusions of the report.
1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE
1.1 Market Definition and Statistical Scope of Active Pharmaceutical Ingredients (API) CDMO
1.2 Key Market Segments
1.2.1 Active Pharmaceutical Ingredients (API) CDMO Segment by Type
1.2.2 Active Pharmaceutical Ingredients (API) CDMO Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 ACTIVE PHARMACEUTICAL INGREDIENTS (API) CDMO MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Active Pharmaceutical Ingredients (API) CDMO Market Size (M USD) Estimates and Forecasts (2019-2032)
2.1.2 Global Active Pharmaceutical Ingredients (API) CDMO Sales Estimates and Forecasts (2019-2032)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 ACTIVE PHARMACEUTICAL INGREDIENTS (API) CDMO MARKET COMPETITIVE LANDSCAPE
3.1 Global Active Pharmaceutical Ingredients (API) CDMO Sales by Manufacturers (2019-2024)
3.2 Global Active Pharmaceutical Ingredients (API) CDMO Revenue Market Share by Manufacturers (2019-2024)
3.3 Active Pharmaceutical Ingredients (API) CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Active Pharmaceutical Ingredients (API) CDMO Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Active Pharmaceutical Ingredients (API) CDMO Sales Sites, Area Served, Product Type
3.6 Active Pharmaceutical Ingredients (API) CDMO Market Competitive Situation and Trends
3.6.1 Active Pharmaceutical Ingredients (API) CDMO Market Concentration Rate
3.6.2 Global 5 and 10 Largest Active Pharmaceutical Ingredients (API) CDMO Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 ACTIVE PHARMACEUTICAL INGREDIENTS (API) CDMO INDUSTRY CHAIN ANALYSIS
4.1 Active Pharmaceutical Ingredients (API) CDMO Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF ACTIVE PHARMACEUTICAL INGREDIENTS (API) CDMO MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 ACTIVE PHARMACEUTICAL INGREDIENTS (API) CDMO MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Active Pharmaceutical Ingredients (API) CDMO Sales Market Share by Type (2019-2024)
6.3 Global Active Pharmaceutical Ingredients (API) CDMO Market Size Market Share by Type (2019-2024)
6.4 Global Active Pharmaceutical Ingredients (API) CDMO Price by Type (2019-2024)
7 ACTIVE PHARMACEUTICAL INGREDIENTS (API) CDMO MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Active Pharmaceutical Ingredients (API) CDMO Market Sales by Application (2019-2024)
7.3 Global Active Pharmaceutical Ingredients (API) CDMO Market Size (M USD) by Application (2019-2024)
7.4 Global Active Pharmaceutical Ingredients (API) CDMO Sales Growth Rate by Application (2019-2024)
8 ACTIVE PHARMACEUTICAL INGREDIENTS (API) CDMO MARKET CONSUMPTION BY REGION
8.1 Global Active Pharmaceutical Ingredients (API) CDMO Sales by Region
8.1.1 Global Active Pharmaceutical Ingredients (API) CDMO Sales by Region
8.1.2 Global Active Pharmaceutical Ingredients (API) CDMO Sales Market Share by Region
8.2 North America
8.2.1 North America Active Pharmaceutical Ingredients (API) CDMO Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Active Pharmaceutical Ingredients (API) CDMO Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Active Pharmaceutical Ingredients (API) CDMO Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Active Pharmaceutical Ingredients (API) CDMO Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Active Pharmaceutical Ingredients (API) CDMO Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 ACTIVE PHARMACEUTICAL INGREDIENTS (API) CDMO MARKET PRODUCTION BY REGION
9.1 Global Production of Active Pharmaceutical Ingredients (API) CDMO by Region (2019-2024)
9.2 Global Active Pharmaceutical Ingredients (API) CDMO Revenue Market Share by Region (2019-2024)
9.3 Global Active Pharmaceutical Ingredients (API) CDMO Production, Revenue, Price and Gross Margin (2019-2024)
9.4 North America Active Pharmaceutical Ingredients (API) CDMO Production
9.4.1 North America Active Pharmaceutical Ingredients (API) CDMO Production Growth Rate (2019-2024)
9.4.2 North America Active Pharmaceutical Ingredients (API) CDMO Production, Revenue, Price and Gross Margin (2019-2024)
9.5 Europe Active Pharmaceutical Ingredients (API) CDMO Production
9.5.1 Europe Active Pharmaceutical Ingredients (API) CDMO Production Growth Rate (2019-2024)
9.5.2 Europe Active Pharmaceutical Ingredients (API) CDMO Production, Revenue, Price and Gross Margin (2019-2024)
9.6 Japan Active Pharmaceutical Ingredients (API) CDMO Production (2019-2024)
9.6.1 Japan Active Pharmaceutical Ingredients (API) CDMO Production Growth Rate (2019-2024)
9.6.2 Japan Active Pharmaceutical Ingredients (API) CDMO Production, Revenue, Price and Gross Margin (2019-2024)
9.7 China Active Pharmaceutical Ingredients (API) CDMO Production (2019-2024)
9.7.1 China Active Pharmaceutical Ingredients (API) CDMO Production Growth Rate (2019-2024)
9.7.2 China Active Pharmaceutical Ingredients (API) CDMO Production, Revenue, Price and Gross Margin (2019-2024)
10 KEY COMPANIES PROFILE
10.1 Recipharm
10.1.1 Recipharm Active Pharmaceutical Ingredients (API) CDMO Basic Information
10.1.2 Recipharm Active Pharmaceutical Ingredients (API) CDMO Product Overview
10.1.3 Recipharm Active Pharmaceutical Ingredients (API) CDMO Product Market Performance
10.1.4 Recipharm Business Overview
10.1.5 Recipharm Active Pharmaceutical Ingredients (API) CDMO SWOT Analysis
10.1.6 Recipharm Recent Developments
10.2 Cambrex Corporation
10.2.1 Cambrex Corporation Active Pharmaceutical Ingredients (API) CDMO Basic Information
10.2.2 Cambrex Corporation Active Pharmaceutical Ingredients (API) CDMO Product Overview
10.2.3 Cambrex Corporation Active Pharmaceutical Ingredients (API) CDMO Product Market Performance
10.2.4 Cambrex Corporation Business Overview
10.2.5 Cambrex Corporation Active Pharmaceutical Ingredients (API) CDMO SWOT Analysis
10.2.6 Cambrex Corporation Recent Developments
10.3 Patheon (Thermo Fisher Scientific)
10.3.1 Patheon (Thermo Fisher Scientific) Active Pharmaceutical Ingredients (API) CDMO Basic Information
10.3.2 Patheon (Thermo Fisher Scientific) Active Pharmaceutical Ingredients (API) CDMO Product Overview
10.3.3 Patheon (Thermo Fisher Scientific) Active Pharmaceutical Ingredients (API) CDMO Product Market Performance
10.3.4 Patheon (Thermo Fisher Scientific) Active Pharmaceutical Ingredients (API) CDMO SWOT Analysis
10.3.5 Patheon (Thermo Fisher Scientific) Business Overview
10.3.6 Patheon (Thermo Fisher Scientific) Recent Developments
10.4 CordenPharma
10.4.1 CordenPharma Active Pharmaceutical Ingredients (API) CDMO Basic Information
10.4.2 CordenPharma Active Pharmaceutical Ingredients (API) CDMO Product Overview
10.4.3 CordenPharma Active Pharmaceutical Ingredients (API) CDMO Product Market Performance
10.4.4 CordenPharma Business Overview
10.4.5 CordenPharma Recent Developments
10.5 Lonza
10.5.1 Lonza Active Pharmaceutical Ingredients (API) CDMO Basic Information
10.5.2 Lonza Active Pharmaceutical Ingredients (API) CDMO Product Overview
10.5.3 Lonza Active Pharmaceutical Ingredients (API) CDMO Product Market Performance
10.5.4 Lonza Business Overview
10.5.5 Lonza Recent Developments
10.6 Siegfried
10.6.1 Siegfried Active Pharmaceutical Ingredients (API) CDMO Basic Information
10.6.2 Siegfried Active Pharmaceutical Ingredients (API) CDMO Product Overview
10.6.3 Siegfried Active Pharmaceutical Ingredients (API) CDMO Product Market Performance
10.6.4 Siegfried Business Overview
10.6.5 Siegfried Recent Developments
10.7 Catalent
10.7.1 Catalent Active Pharmaceutical Ingredients (API) CDMO Basic Information
10.7.2 Catalent Active Pharmaceutical Ingredients (API) CDMO Product Overview
10.7.3 Catalent Active Pharmaceutical Ingredients (API) CDMO Product Market Performance
10.7.4 Catalent Business Overview
10.7.5 Catalent Recent Developments
10.8 Boehringer Ingelheim
10.8.1 Boehringer Ingelheim Active Pharmaceutical Ingredients (API) CDMO Basic Information
10.8.2 Boehringer Ingelheim Active Pharmaceutical Ingredients (API) CDMO Product Overview
10.8.3 Boehringer Ingelheim Active Pharmaceutical Ingredients (API) CDMO Product Market Performance
10.8.4 Boehringer Ingelheim Business Overview
10.8.5 Boehringer Ingelheim Recent Developments
10.9 Piramal Group
10.9.1 Piramal Group Active Pharmaceutical Ingredients (API) CDMO Basic Information
10.9.2 Piramal Group Active Pharmaceutical Ingredients (API) CDMO Product Overview
10.9.3 Piramal Group Active Pharmaceutical Ingredients (API) CDMO Product Market Performance
10.9.4 Piramal Group Business Overview
10.9.5 Piramal Group Recent Developments
10.10 AbbVie
10.10.1 AbbVie Active Pharmaceutical Ingredients (API) CDMO Basic Information
10.10.2 AbbVie Active Pharmaceutical Ingredients (API) CDMO Product Overview
10.10.3 AbbVie Active Pharmaceutical Ingredients (API) CDMO Product Market Performance
10.10.4 AbbVie Business Overview
10.10.5 AbbVie Recent Developments
10.11 SGS Quay Pharmaceuticals
10.11.1 SGS Quay Pharmaceuticals Active Pharmaceutical Ingredients (API) CDMO Basic Information
10.11.2 SGS Quay Pharmaceuticals Active Pharmaceutical Ingredients (API) CDMO Product Overview
10.11.3 SGS Quay Pharmaceuticals Active Pharmaceutical Ingredients (API) CDMO Product Market Performance
10.11.4 SGS Quay Pharmaceuticals Business Overview
10.11.5 SGS Quay Pharmaceuticals Recent Developments
10.12 Aenova Group
10.12.1 Aenova Group Active Pharmaceutical Ingredients (API) CDMO Basic Information
10.12.2 Aenova Group Active Pharmaceutical Ingredients (API) CDMO Product Overview
10.12.3 Aenova Group Active Pharmaceutical Ingredients (API) CDMO Product Market Performance
10.12.4 Aenova Group Business Overview
10.12.5 Aenova Group Recent Developments
10.13 Curia
10.13.1 Curia Active Pharmaceutical Ingredients (API) CDMO Basic Information
10.13.2 Curia Active Pharmaceutical Ingredients (API) CDMO Product Overview
10.13.3 Curia Active Pharmaceutical Ingredients (API) CDMO Product Market Performance
10.13.4 Curia Business Overview
10.13.5 Curia Recent Developments
10.14 Sterling Pharma Solutions
10.14.1 Sterling Pharma Solutions Active Pharmaceutical Ingredients (API) CDMO Basic Information
10.14.2 Sterling Pharma Solutions Active Pharmaceutical Ingredients (API) CDMO Product Overview
10.14.3 Sterling Pharma Solutions Active Pharmaceutical Ingredients (API) CDMO Product Market Performance
10.14.4 Sterling Pharma Solutions Business Overview
10.14.5 Sterling Pharma Solutions Recent Developments
10.15 Eurofins CDMO
10.15.1 Eurofins CDMO Active Pharmaceutical Ingredients (API) CDMO Basic Information
10.15.2 Eurofins CDMO Active Pharmaceutical Ingredients (API) CDMO Product Overview
10.15.3 Eurofins CDMO Active Pharmaceutical Ingredients (API) CDMO Product Market Performance
10.15.4 Eurofins CDMO Business Overview
10.15.5 Eurofins CDMO Recent Developments
11 ACTIVE PHARMACEUTICAL INGREDIENTS (API) CDMO MARKET FORECAST BY REGION
11.1 Global Active Pharmaceutical Ingredients (API) CDMO Market Size Forecast
11.2 Global Active Pharmaceutical Ingredients (API) CDMO Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Active Pharmaceutical Ingredients (API) CDMO Market Size Forecast by Country
11.2.3 Asia Pacific Active Pharmaceutical Ingredients (API) CDMO Market Size Forecast by Region
11.2.4 South America Active Pharmaceutical Ingredients (API) CDMO Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Consumption of Active Pharmaceutical Ingredients (API) CDMO by Country
12 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2032)
12.1 Global Active Pharmaceutical Ingredients (API) CDMO Market Forecast by Type (2025-2032)
12.1.1 Global Forecasted Sales of Active Pharmaceutical Ingredients (API) CDMO by Type (2025-2032)
12.1.2 Global Active Pharmaceutical Ingredients (API) CDMO Market Size Forecast by Type (2025-2032)
12.1.3 Global Forecasted Price of Active Pharmaceutical Ingredients (API) CDMO by Type (2025-2032)
12.2 Global Active Pharmaceutical Ingredients (API) CDMO Market Forecast by Application (2025-2032)
12.2.1 Global Active Pharmaceutical Ingredients (API) CDMO Sales (K Units) Forecast by Application
12.2.2 Global Active Pharmaceutical Ingredients (API) CDMO Market Size (M USD) Forecast by Application (2025-2032)
13 CONCLUSION AND KEY FINDINGS
1.1 Market Definition and Statistical Scope of Active Pharmaceutical Ingredients (API) CDMO
1.2 Key Market Segments
1.2.1 Active Pharmaceutical Ingredients (API) CDMO Segment by Type
1.2.2 Active Pharmaceutical Ingredients (API) CDMO Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 ACTIVE PHARMACEUTICAL INGREDIENTS (API) CDMO MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Active Pharmaceutical Ingredients (API) CDMO Market Size (M USD) Estimates and Forecasts (2019-2032)
2.1.2 Global Active Pharmaceutical Ingredients (API) CDMO Sales Estimates and Forecasts (2019-2032)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 ACTIVE PHARMACEUTICAL INGREDIENTS (API) CDMO MARKET COMPETITIVE LANDSCAPE
3.1 Global Active Pharmaceutical Ingredients (API) CDMO Sales by Manufacturers (2019-2024)
3.2 Global Active Pharmaceutical Ingredients (API) CDMO Revenue Market Share by Manufacturers (2019-2024)
3.3 Active Pharmaceutical Ingredients (API) CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Active Pharmaceutical Ingredients (API) CDMO Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Active Pharmaceutical Ingredients (API) CDMO Sales Sites, Area Served, Product Type
3.6 Active Pharmaceutical Ingredients (API) CDMO Market Competitive Situation and Trends
3.6.1 Active Pharmaceutical Ingredients (API) CDMO Market Concentration Rate
3.6.2 Global 5 and 10 Largest Active Pharmaceutical Ingredients (API) CDMO Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 ACTIVE PHARMACEUTICAL INGREDIENTS (API) CDMO INDUSTRY CHAIN ANALYSIS
4.1 Active Pharmaceutical Ingredients (API) CDMO Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF ACTIVE PHARMACEUTICAL INGREDIENTS (API) CDMO MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 ACTIVE PHARMACEUTICAL INGREDIENTS (API) CDMO MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Active Pharmaceutical Ingredients (API) CDMO Sales Market Share by Type (2019-2024)
6.3 Global Active Pharmaceutical Ingredients (API) CDMO Market Size Market Share by Type (2019-2024)
6.4 Global Active Pharmaceutical Ingredients (API) CDMO Price by Type (2019-2024)
7 ACTIVE PHARMACEUTICAL INGREDIENTS (API) CDMO MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Active Pharmaceutical Ingredients (API) CDMO Market Sales by Application (2019-2024)
7.3 Global Active Pharmaceutical Ingredients (API) CDMO Market Size (M USD) by Application (2019-2024)
7.4 Global Active Pharmaceutical Ingredients (API) CDMO Sales Growth Rate by Application (2019-2024)
8 ACTIVE PHARMACEUTICAL INGREDIENTS (API) CDMO MARKET CONSUMPTION BY REGION
8.1 Global Active Pharmaceutical Ingredients (API) CDMO Sales by Region
8.1.1 Global Active Pharmaceutical Ingredients (API) CDMO Sales by Region
8.1.2 Global Active Pharmaceutical Ingredients (API) CDMO Sales Market Share by Region
8.2 North America
8.2.1 North America Active Pharmaceutical Ingredients (API) CDMO Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Active Pharmaceutical Ingredients (API) CDMO Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Active Pharmaceutical Ingredients (API) CDMO Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Active Pharmaceutical Ingredients (API) CDMO Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Active Pharmaceutical Ingredients (API) CDMO Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 ACTIVE PHARMACEUTICAL INGREDIENTS (API) CDMO MARKET PRODUCTION BY REGION
9.1 Global Production of Active Pharmaceutical Ingredients (API) CDMO by Region (2019-2024)
9.2 Global Active Pharmaceutical Ingredients (API) CDMO Revenue Market Share by Region (2019-2024)
9.3 Global Active Pharmaceutical Ingredients (API) CDMO Production, Revenue, Price and Gross Margin (2019-2024)
9.4 North America Active Pharmaceutical Ingredients (API) CDMO Production
9.4.1 North America Active Pharmaceutical Ingredients (API) CDMO Production Growth Rate (2019-2024)
9.4.2 North America Active Pharmaceutical Ingredients (API) CDMO Production, Revenue, Price and Gross Margin (2019-2024)
9.5 Europe Active Pharmaceutical Ingredients (API) CDMO Production
9.5.1 Europe Active Pharmaceutical Ingredients (API) CDMO Production Growth Rate (2019-2024)
9.5.2 Europe Active Pharmaceutical Ingredients (API) CDMO Production, Revenue, Price and Gross Margin (2019-2024)
9.6 Japan Active Pharmaceutical Ingredients (API) CDMO Production (2019-2024)
9.6.1 Japan Active Pharmaceutical Ingredients (API) CDMO Production Growth Rate (2019-2024)
9.6.2 Japan Active Pharmaceutical Ingredients (API) CDMO Production, Revenue, Price and Gross Margin (2019-2024)
9.7 China Active Pharmaceutical Ingredients (API) CDMO Production (2019-2024)
9.7.1 China Active Pharmaceutical Ingredients (API) CDMO Production Growth Rate (2019-2024)
9.7.2 China Active Pharmaceutical Ingredients (API) CDMO Production, Revenue, Price and Gross Margin (2019-2024)
10 KEY COMPANIES PROFILE
10.1 Recipharm
10.1.1 Recipharm Active Pharmaceutical Ingredients (API) CDMO Basic Information
10.1.2 Recipharm Active Pharmaceutical Ingredients (API) CDMO Product Overview
10.1.3 Recipharm Active Pharmaceutical Ingredients (API) CDMO Product Market Performance
10.1.4 Recipharm Business Overview
10.1.5 Recipharm Active Pharmaceutical Ingredients (API) CDMO SWOT Analysis
10.1.6 Recipharm Recent Developments
10.2 Cambrex Corporation
10.2.1 Cambrex Corporation Active Pharmaceutical Ingredients (API) CDMO Basic Information
10.2.2 Cambrex Corporation Active Pharmaceutical Ingredients (API) CDMO Product Overview
10.2.3 Cambrex Corporation Active Pharmaceutical Ingredients (API) CDMO Product Market Performance
10.2.4 Cambrex Corporation Business Overview
10.2.5 Cambrex Corporation Active Pharmaceutical Ingredients (API) CDMO SWOT Analysis
10.2.6 Cambrex Corporation Recent Developments
10.3 Patheon (Thermo Fisher Scientific)
10.3.1 Patheon (Thermo Fisher Scientific) Active Pharmaceutical Ingredients (API) CDMO Basic Information
10.3.2 Patheon (Thermo Fisher Scientific) Active Pharmaceutical Ingredients (API) CDMO Product Overview
10.3.3 Patheon (Thermo Fisher Scientific) Active Pharmaceutical Ingredients (API) CDMO Product Market Performance
10.3.4 Patheon (Thermo Fisher Scientific) Active Pharmaceutical Ingredients (API) CDMO SWOT Analysis
10.3.5 Patheon (Thermo Fisher Scientific) Business Overview
10.3.6 Patheon (Thermo Fisher Scientific) Recent Developments
10.4 CordenPharma
10.4.1 CordenPharma Active Pharmaceutical Ingredients (API) CDMO Basic Information
10.4.2 CordenPharma Active Pharmaceutical Ingredients (API) CDMO Product Overview
10.4.3 CordenPharma Active Pharmaceutical Ingredients (API) CDMO Product Market Performance
10.4.4 CordenPharma Business Overview
10.4.5 CordenPharma Recent Developments
10.5 Lonza
10.5.1 Lonza Active Pharmaceutical Ingredients (API) CDMO Basic Information
10.5.2 Lonza Active Pharmaceutical Ingredients (API) CDMO Product Overview
10.5.3 Lonza Active Pharmaceutical Ingredients (API) CDMO Product Market Performance
10.5.4 Lonza Business Overview
10.5.5 Lonza Recent Developments
10.6 Siegfried
10.6.1 Siegfried Active Pharmaceutical Ingredients (API) CDMO Basic Information
10.6.2 Siegfried Active Pharmaceutical Ingredients (API) CDMO Product Overview
10.6.3 Siegfried Active Pharmaceutical Ingredients (API) CDMO Product Market Performance
10.6.4 Siegfried Business Overview
10.6.5 Siegfried Recent Developments
10.7 Catalent
10.7.1 Catalent Active Pharmaceutical Ingredients (API) CDMO Basic Information
10.7.2 Catalent Active Pharmaceutical Ingredients (API) CDMO Product Overview
10.7.3 Catalent Active Pharmaceutical Ingredients (API) CDMO Product Market Performance
10.7.4 Catalent Business Overview
10.7.5 Catalent Recent Developments
10.8 Boehringer Ingelheim
10.8.1 Boehringer Ingelheim Active Pharmaceutical Ingredients (API) CDMO Basic Information
10.8.2 Boehringer Ingelheim Active Pharmaceutical Ingredients (API) CDMO Product Overview
10.8.3 Boehringer Ingelheim Active Pharmaceutical Ingredients (API) CDMO Product Market Performance
10.8.4 Boehringer Ingelheim Business Overview
10.8.5 Boehringer Ingelheim Recent Developments
10.9 Piramal Group
10.9.1 Piramal Group Active Pharmaceutical Ingredients (API) CDMO Basic Information
10.9.2 Piramal Group Active Pharmaceutical Ingredients (API) CDMO Product Overview
10.9.3 Piramal Group Active Pharmaceutical Ingredients (API) CDMO Product Market Performance
10.9.4 Piramal Group Business Overview
10.9.5 Piramal Group Recent Developments
10.10 AbbVie
10.10.1 AbbVie Active Pharmaceutical Ingredients (API) CDMO Basic Information
10.10.2 AbbVie Active Pharmaceutical Ingredients (API) CDMO Product Overview
10.10.3 AbbVie Active Pharmaceutical Ingredients (API) CDMO Product Market Performance
10.10.4 AbbVie Business Overview
10.10.5 AbbVie Recent Developments
10.11 SGS Quay Pharmaceuticals
10.11.1 SGS Quay Pharmaceuticals Active Pharmaceutical Ingredients (API) CDMO Basic Information
10.11.2 SGS Quay Pharmaceuticals Active Pharmaceutical Ingredients (API) CDMO Product Overview
10.11.3 SGS Quay Pharmaceuticals Active Pharmaceutical Ingredients (API) CDMO Product Market Performance
10.11.4 SGS Quay Pharmaceuticals Business Overview
10.11.5 SGS Quay Pharmaceuticals Recent Developments
10.12 Aenova Group
10.12.1 Aenova Group Active Pharmaceutical Ingredients (API) CDMO Basic Information
10.12.2 Aenova Group Active Pharmaceutical Ingredients (API) CDMO Product Overview
10.12.3 Aenova Group Active Pharmaceutical Ingredients (API) CDMO Product Market Performance
10.12.4 Aenova Group Business Overview
10.12.5 Aenova Group Recent Developments
10.13 Curia
10.13.1 Curia Active Pharmaceutical Ingredients (API) CDMO Basic Information
10.13.2 Curia Active Pharmaceutical Ingredients (API) CDMO Product Overview
10.13.3 Curia Active Pharmaceutical Ingredients (API) CDMO Product Market Performance
10.13.4 Curia Business Overview
10.13.5 Curia Recent Developments
10.14 Sterling Pharma Solutions
10.14.1 Sterling Pharma Solutions Active Pharmaceutical Ingredients (API) CDMO Basic Information
10.14.2 Sterling Pharma Solutions Active Pharmaceutical Ingredients (API) CDMO Product Overview
10.14.3 Sterling Pharma Solutions Active Pharmaceutical Ingredients (API) CDMO Product Market Performance
10.14.4 Sterling Pharma Solutions Business Overview
10.14.5 Sterling Pharma Solutions Recent Developments
10.15 Eurofins CDMO
10.15.1 Eurofins CDMO Active Pharmaceutical Ingredients (API) CDMO Basic Information
10.15.2 Eurofins CDMO Active Pharmaceutical Ingredients (API) CDMO Product Overview
10.15.3 Eurofins CDMO Active Pharmaceutical Ingredients (API) CDMO Product Market Performance
10.15.4 Eurofins CDMO Business Overview
10.15.5 Eurofins CDMO Recent Developments
11 ACTIVE PHARMACEUTICAL INGREDIENTS (API) CDMO MARKET FORECAST BY REGION
11.1 Global Active Pharmaceutical Ingredients (API) CDMO Market Size Forecast
11.2 Global Active Pharmaceutical Ingredients (API) CDMO Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Active Pharmaceutical Ingredients (API) CDMO Market Size Forecast by Country
11.2.3 Asia Pacific Active Pharmaceutical Ingredients (API) CDMO Market Size Forecast by Region
11.2.4 South America Active Pharmaceutical Ingredients (API) CDMO Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Consumption of Active Pharmaceutical Ingredients (API) CDMO by Country
12 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2032)
12.1 Global Active Pharmaceutical Ingredients (API) CDMO Market Forecast by Type (2025-2032)
12.1.1 Global Forecasted Sales of Active Pharmaceutical Ingredients (API) CDMO by Type (2025-2032)
12.1.2 Global Active Pharmaceutical Ingredients (API) CDMO Market Size Forecast by Type (2025-2032)
12.1.3 Global Forecasted Price of Active Pharmaceutical Ingredients (API) CDMO by Type (2025-2032)
12.2 Global Active Pharmaceutical Ingredients (API) CDMO Market Forecast by Application (2025-2032)
12.2.1 Global Active Pharmaceutical Ingredients (API) CDMO Sales (K Units) Forecast by Application
12.2.2 Global Active Pharmaceutical Ingredients (API) CDMO Market Size (M USD) Forecast by Application (2025-2032)
13 CONCLUSION AND KEY FINDINGS
LIST OF TABLES
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Active Pharmaceutical Ingredients (API) CDMO Market Size Comparison by Region (M USD)
Table 5. Global Active Pharmaceutical Ingredients (API) CDMO Sales (K Units) by Manufacturers (2019-2024)
Table 6. Global Active Pharmaceutical Ingredients (API) CDMO Sales Market Share by Manufacturers (2019-2024)
Table 7. Global Active Pharmaceutical Ingredients (API) CDMO Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global Active Pharmaceutical Ingredients (API) CDMO Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Active Pharmaceutical Ingredients (API) CDMO as of 2022)
Table 10. Global Market Active Pharmaceutical Ingredients (API) CDMO Average Price (USD/Unit) of Key Manufacturers (2019-2024)
Table 11. Manufacturers Active Pharmaceutical Ingredients (API) CDMO Sales Sites and Area Served
Table 12. Manufacturers Active Pharmaceutical Ingredients (API) CDMO Product Type
Table 13. Global Active Pharmaceutical Ingredients (API) CDMO Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Active Pharmaceutical Ingredients (API) CDMO
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Active Pharmaceutical Ingredients (API) CDMO Market Challenges
Table 22. Global Active Pharmaceutical Ingredients (API) CDMO Sales by Type (K Units)
Table 23. Global Active Pharmaceutical Ingredients (API) CDMO Market Size by Type (M USD)
Table 24. Global Active Pharmaceutical Ingredients (API) CDMO Sales (K Units) by Type (2019-2024)
Table 25. Global Active Pharmaceutical Ingredients (API) CDMO Sales Market Share by Type (2019-2024)
Table 26. Global Active Pharmaceutical Ingredients (API) CDMO Market Size (M USD) by Type (2019-2024)
Table 27. Global Active Pharmaceutical Ingredients (API) CDMO Market Size Share by Type (2019-2024)
Table 28. Global Active Pharmaceutical Ingredients (API) CDMO Price (USD/Unit) by Type (2019-2024)
Table 29. Global Active Pharmaceutical Ingredients (API) CDMO Sales (K Units) by Application
Table 30. Global Active Pharmaceutical Ingredients (API) CDMO Market Size by Application
Table 31. Global Active Pharmaceutical Ingredients (API) CDMO Sales by Application (2019-2024) & (K Units)
Table 32. Global Active Pharmaceutical Ingredients (API) CDMO Sales Market Share by Application (2019-2024)
Table 33. Global Active Pharmaceutical Ingredients (API) CDMO Sales by Application (2019-2024) & (M USD)
Table 34. Global Active Pharmaceutical Ingredients (API) CDMO Market Share by Application (2019-2024)
Table 35. Global Active Pharmaceutical Ingredients (API) CDMO Sales Growth Rate by Application (2019-2024)
Table 36. Global Active Pharmaceutical Ingredients (API) CDMO Sales by Region (2019-2024) & (K Units)
Table 37. Global Active Pharmaceutical Ingredients (API) CDMO Sales Market Share by Region (2019-2024)
Table 38. North America Active Pharmaceutical Ingredients (API) CDMO Sales by Country (2019-2024) & (K Units)
Table 39. Europe Active Pharmaceutical Ingredients (API) CDMO Sales by Country (2019-2024) & (K Units)
Table 40. Asia Pacific Active Pharmaceutical Ingredients (API) CDMO Sales by Region (2019-2024) & (K Units)
Table 41. South America Active Pharmaceutical Ingredients (API) CDMO Sales by Country (2019-2024) & (K Units)
Table 42. Middle East and Africa Active Pharmaceutical Ingredients (API) CDMO Sales by Region (2019-2024) & (K Units)
Table 43. Global Active Pharmaceutical Ingredients (API) CDMO Production (K Units) by Region (2019-2024)
Table 44. Global Active Pharmaceutical Ingredients (API) CDMO Revenue (US$ Million) by Region (2019-2024)
Table 45. Global Active Pharmaceutical Ingredients (API) CDMO Revenue Market Share by Region (2019-2024)
Table 46. Global Active Pharmaceutical Ingredients (API) CDMO Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 47. North America Active Pharmaceutical Ingredients (API) CDMO Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 48. Europe Active Pharmaceutical Ingredients (API) CDMO Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 49. Japan Active Pharmaceutical Ingredients (API) CDMO Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 50. China Active Pharmaceutical Ingredients (API) CDMO Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 51. Recipharm Active Pharmaceutical Ingredients (API) CDMO Basic Information
Table 52. Recipharm Active Pharmaceutical Ingredients (API) CDMO Product Overview
Table 53. Recipharm Active Pharmaceutical Ingredients (API) CDMO Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 54. Recipharm Business Overview
Table 55. Recipharm Active Pharmaceutical Ingredients (API) CDMO SWOT Analysis
Table 56. Recipharm Recent Developments
Table 57. Cambrex Corporation Active Pharmaceutical Ingredients (API) CDMO Basic Information
Table 58. Cambrex Corporation Active Pharmaceutical Ingredients (API) CDMO Product Overview
Table 59. Cambrex Corporation Active Pharmaceutical Ingredients (API) CDMO Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 60. Cambrex Corporation Business Overview
Table 61. Cambrex Corporation Active Pharmaceutical Ingredients (API) CDMO SWOT Analysis
Table 62. Cambrex Corporation Recent Developments
Table 63. Patheon (Thermo Fisher Scientific) Active Pharmaceutical Ingredients (API) CDMO Basic Information
Table 64. Patheon (Thermo Fisher Scientific) Active Pharmaceutical Ingredients (API) CDMO Product Overview
Table 65. Patheon (Thermo Fisher Scientific) Active Pharmaceutical Ingredients (API) CDMO Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 66. Patheon (Thermo Fisher Scientific) Active Pharmaceutical Ingredients (API) CDMO SWOT Analysis
Table 67. Patheon (Thermo Fisher Scientific) Business Overview
Table 68. Patheon (Thermo Fisher Scientific) Recent Developments
Table 69. CordenPharma Active Pharmaceutical Ingredients (API) CDMO Basic Information
Table 70. CordenPharma Active Pharmaceutical Ingredients (API) CDMO Product Overview
Table 71. CordenPharma Active Pharmaceutical Ingredients (API) CDMO Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 72. CordenPharma Business Overview
Table 73. CordenPharma Recent Developments
Table 74. Lonza Active Pharmaceutical Ingredients (API) CDMO Basic Information
Table 75. Lonza Active Pharmaceutical Ingredients (API) CDMO Product Overview
Table 76. Lonza Active Pharmaceutical Ingredients (API) CDMO Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 77. Lonza Business Overview
Table 78. Lonza Recent Developments
Table 79. Siegfried Active Pharmaceutical Ingredients (API) CDMO Basic Information
Table 80. Siegfried Active Pharmaceutical Ingredients (API) CDMO Product Overview
Table 81. Siegfried Active Pharmaceutical Ingredients (API) CDMO Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 82. Siegfried Business Overview
Table 83. Siegfried Recent Developments
Table 84. Catalent Active Pharmaceutical Ingredients (API) CDMO Basic Information
Table 85. Catalent Active Pharmaceutical Ingredients (API) CDMO Product Overview
Table 86. Catalent Active Pharmaceutical Ingredients (API) CDMO Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 87. Catalent Business Overview
Table 88. Catalent Recent Developments
Table 89. Boehringer Ingelheim Active Pharmaceutical Ingredients (API) CDMO Basic Information
Table 90. Boehringer Ingelheim Active Pharmaceutical Ingredients (API) CDMO Product Overview
Table 91. Boehringer Ingelheim Active Pharmaceutical Ingredients (API) CDMO Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 92. Boehringer Ingelheim Business Overview
Table 93. Boehringer Ingelheim Recent Developments
Table 94. Piramal Group Active Pharmaceutical Ingredients (API) CDMO Basic Information
Table 95. Piramal Group Active Pharmaceutical Ingredients (API) CDMO Product Overview
Table 96. Piramal Group Active Pharmaceutical Ingredients (API) CDMO Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 97. Piramal Group Business Overview
Table 98. Piramal Group Recent Developments
Table 99. AbbVie Active Pharmaceutical Ingredients (API) CDMO Basic Information
Table 100. AbbVie Active Pharmaceutical Ingredients (API) CDMO Product Overview
Table 101. AbbVie Active Pharmaceutical Ingredients (API) CDMO Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 102. AbbVie Business Overview
Table 103. AbbVie Recent Developments
Table 104. SGS Quay Pharmaceuticals Active Pharmaceutical Ingredients (API) CDMO Basic Information
Table 105. SGS Quay Pharmaceuticals Active Pharmaceutical Ingredients (API) CDMO Product Overview
Table 106. SGS Quay Pharmaceuticals Active Pharmaceutical Ingredients (API) CDMO Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 107. SGS Quay Pharmaceuticals Business Overview
Table 108. SGS Quay Pharmaceuticals Recent Developments
Table 109. Aenova Group Active Pharmaceutical Ingredients (API) CDMO Basic Information
Table 110. Aenova Group Active Pharmaceutical Ingredients (API) CDMO Product Overview
Table 111. Aenova Group Active Pharmaceutical Ingredients (API) CDMO Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 112. Aenova Group Business Overview
Table 113. Aenova Group Recent Developments
Table 114. Curia Active Pharmaceutical Ingredients (API) CDMO Basic Information
Table 115. Curia Active Pharmaceutical Ingredients (API) CDMO Product Overview
Table 116. Curia Active Pharmaceutical Ingredients (API) CDMO Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 117. Curia Business Overview
Table 118. Curia Recent Developments
Table 119. Sterling Pharma Solutions Active Pharmaceutical Ingredients (API) CDMO Basic Information
Table 120. Sterling Pharma Solutions Active Pharmaceutical Ingredients (API) CDMO Product Overview
Table 121. Sterling Pharma Solutions Active Pharmaceutical Ingredients (API) CDMO Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 122. Sterling Pharma Solutions Business Overview
Table 123. Sterling Pharma Solutions Recent Developments
Table 124. Eurofins CDMO Active Pharmaceutical Ingredients (API) CDMO Basic Information
Table 125. Eurofins CDMO Active Pharmaceutical Ingredients (API) CDMO Product Overview
Table 126. Eurofins CDMO Active Pharmaceutical Ingredients (API) CDMO Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 127. Eurofins CDMO Business Overview
Table 128. Eurofins CDMO Recent Developments
Table 129. Global Active Pharmaceutical Ingredients (API) CDMO Sales Forecast by Region (2025-2032) & (K Units)
Table 130. Global Active Pharmaceutical Ingredients (API) CDMO Market Size Forecast by Region (2025-2032) & (M USD)
Table 131. North America Active Pharmaceutical Ingredients (API) CDMO Sales Forecast by Country (2025-2032) & (K Units)
Table 132. North America Active Pharmaceutical Ingredients (API) CDMO Market Size Forecast by Country (2025-2032) & (M USD)
Table 133. Europe Active Pharmaceutical Ingredients (API) CDMO Sales Forecast by Country (2025-2032) & (K Units)
Table 134. Europe Active Pharmaceutical Ingredients (API) CDMO Market Size Forecast by Country (2025-2032) & (M USD)
Table 135. Asia Pacific Active Pharmaceutical Ingredients (API) CDMO Sales Forecast by Region (2025-2032) & (K Units)
Table 136. Asia Pacific Active Pharmaceutical Ingredients (API) CDMO Market Size Forecast by Region (2025-2032) & (M USD)
Table 137. South America Active Pharmaceutical Ingredients (API) CDMO Sales Forecast by Country (2025-2032) & (K Units)
Table 138. South America Active Pharmaceutical Ingredients (API) CDMO Market Size Forecast by Country (2025-2032) & (M USD)
Table 139. Middle East and Africa Active Pharmaceutical Ingredients (API) CDMO Consumption Forecast by Country (2025-2032) & (Units)
Table 140. Middle East and Africa Active Pharmaceutical Ingredients (API) CDMO Market Size Forecast by Country (2025-2032) & (M USD)
Table 141. Global Active Pharmaceutical Ingredients (API) CDMO Sales Forecast by Type (2025-2032) & (K Units)
Table 142. Global Active Pharmaceutical Ingredients (API) CDMO Market Size Forecast by Type (2025-2032) & (M USD)
Table 143. Global Active Pharmaceutical Ingredients (API) CDMO Price Forecast by Type (2025-2032) & (USD/Unit)
Table 144. Global Active Pharmaceutical Ingredients (API) CDMO Sales (K Units) Forecast by Application (2025-2032)
Table 145. Global Active Pharmaceutical Ingredients (API) CDMO Market Size Forecast by Application (2025-2032) & (M USD)
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Active Pharmaceutical Ingredients (API) CDMO Market Size Comparison by Region (M USD)
Table 5. Global Active Pharmaceutical Ingredients (API) CDMO Sales (K Units) by Manufacturers (2019-2024)
Table 6. Global Active Pharmaceutical Ingredients (API) CDMO Sales Market Share by Manufacturers (2019-2024)
Table 7. Global Active Pharmaceutical Ingredients (API) CDMO Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global Active Pharmaceutical Ingredients (API) CDMO Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Active Pharmaceutical Ingredients (API) CDMO as of 2022)
Table 10. Global Market Active Pharmaceutical Ingredients (API) CDMO Average Price (USD/Unit) of Key Manufacturers (2019-2024)
Table 11. Manufacturers Active Pharmaceutical Ingredients (API) CDMO Sales Sites and Area Served
Table 12. Manufacturers Active Pharmaceutical Ingredients (API) CDMO Product Type
Table 13. Global Active Pharmaceutical Ingredients (API) CDMO Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Active Pharmaceutical Ingredients (API) CDMO
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Active Pharmaceutical Ingredients (API) CDMO Market Challenges
Table 22. Global Active Pharmaceutical Ingredients (API) CDMO Sales by Type (K Units)
Table 23. Global Active Pharmaceutical Ingredients (API) CDMO Market Size by Type (M USD)
Table 24. Global Active Pharmaceutical Ingredients (API) CDMO Sales (K Units) by Type (2019-2024)
Table 25. Global Active Pharmaceutical Ingredients (API) CDMO Sales Market Share by Type (2019-2024)
Table 26. Global Active Pharmaceutical Ingredients (API) CDMO Market Size (M USD) by Type (2019-2024)
Table 27. Global Active Pharmaceutical Ingredients (API) CDMO Market Size Share by Type (2019-2024)
Table 28. Global Active Pharmaceutical Ingredients (API) CDMO Price (USD/Unit) by Type (2019-2024)
Table 29. Global Active Pharmaceutical Ingredients (API) CDMO Sales (K Units) by Application
Table 30. Global Active Pharmaceutical Ingredients (API) CDMO Market Size by Application
Table 31. Global Active Pharmaceutical Ingredients (API) CDMO Sales by Application (2019-2024) & (K Units)
Table 32. Global Active Pharmaceutical Ingredients (API) CDMO Sales Market Share by Application (2019-2024)
Table 33. Global Active Pharmaceutical Ingredients (API) CDMO Sales by Application (2019-2024) & (M USD)
Table 34. Global Active Pharmaceutical Ingredients (API) CDMO Market Share by Application (2019-2024)
Table 35. Global Active Pharmaceutical Ingredients (API) CDMO Sales Growth Rate by Application (2019-2024)
Table 36. Global Active Pharmaceutical Ingredients (API) CDMO Sales by Region (2019-2024) & (K Units)
Table 37. Global Active Pharmaceutical Ingredients (API) CDMO Sales Market Share by Region (2019-2024)
Table 38. North America Active Pharmaceutical Ingredients (API) CDMO Sales by Country (2019-2024) & (K Units)
Table 39. Europe Active Pharmaceutical Ingredients (API) CDMO Sales by Country (2019-2024) & (K Units)
Table 40. Asia Pacific Active Pharmaceutical Ingredients (API) CDMO Sales by Region (2019-2024) & (K Units)
Table 41. South America Active Pharmaceutical Ingredients (API) CDMO Sales by Country (2019-2024) & (K Units)
Table 42. Middle East and Africa Active Pharmaceutical Ingredients (API) CDMO Sales by Region (2019-2024) & (K Units)
Table 43. Global Active Pharmaceutical Ingredients (API) CDMO Production (K Units) by Region (2019-2024)
Table 44. Global Active Pharmaceutical Ingredients (API) CDMO Revenue (US$ Million) by Region (2019-2024)
Table 45. Global Active Pharmaceutical Ingredients (API) CDMO Revenue Market Share by Region (2019-2024)
Table 46. Global Active Pharmaceutical Ingredients (API) CDMO Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 47. North America Active Pharmaceutical Ingredients (API) CDMO Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 48. Europe Active Pharmaceutical Ingredients (API) CDMO Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 49. Japan Active Pharmaceutical Ingredients (API) CDMO Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 50. China Active Pharmaceutical Ingredients (API) CDMO Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 51. Recipharm Active Pharmaceutical Ingredients (API) CDMO Basic Information
Table 52. Recipharm Active Pharmaceutical Ingredients (API) CDMO Product Overview
Table 53. Recipharm Active Pharmaceutical Ingredients (API) CDMO Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 54. Recipharm Business Overview
Table 55. Recipharm Active Pharmaceutical Ingredients (API) CDMO SWOT Analysis
Table 56. Recipharm Recent Developments
Table 57. Cambrex Corporation Active Pharmaceutical Ingredients (API) CDMO Basic Information
Table 58. Cambrex Corporation Active Pharmaceutical Ingredients (API) CDMO Product Overview
Table 59. Cambrex Corporation Active Pharmaceutical Ingredients (API) CDMO Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 60. Cambrex Corporation Business Overview
Table 61. Cambrex Corporation Active Pharmaceutical Ingredients (API) CDMO SWOT Analysis
Table 62. Cambrex Corporation Recent Developments
Table 63. Patheon (Thermo Fisher Scientific) Active Pharmaceutical Ingredients (API) CDMO Basic Information
Table 64. Patheon (Thermo Fisher Scientific) Active Pharmaceutical Ingredients (API) CDMO Product Overview
Table 65. Patheon (Thermo Fisher Scientific) Active Pharmaceutical Ingredients (API) CDMO Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 66. Patheon (Thermo Fisher Scientific) Active Pharmaceutical Ingredients (API) CDMO SWOT Analysis
Table 67. Patheon (Thermo Fisher Scientific) Business Overview
Table 68. Patheon (Thermo Fisher Scientific) Recent Developments
Table 69. CordenPharma Active Pharmaceutical Ingredients (API) CDMO Basic Information
Table 70. CordenPharma Active Pharmaceutical Ingredients (API) CDMO Product Overview
Table 71. CordenPharma Active Pharmaceutical Ingredients (API) CDMO Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 72. CordenPharma Business Overview
Table 73. CordenPharma Recent Developments
Table 74. Lonza Active Pharmaceutical Ingredients (API) CDMO Basic Information
Table 75. Lonza Active Pharmaceutical Ingredients (API) CDMO Product Overview
Table 76. Lonza Active Pharmaceutical Ingredients (API) CDMO Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 77. Lonza Business Overview
Table 78. Lonza Recent Developments
Table 79. Siegfried Active Pharmaceutical Ingredients (API) CDMO Basic Information
Table 80. Siegfried Active Pharmaceutical Ingredients (API) CDMO Product Overview
Table 81. Siegfried Active Pharmaceutical Ingredients (API) CDMO Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 82. Siegfried Business Overview
Table 83. Siegfried Recent Developments
Table 84. Catalent Active Pharmaceutical Ingredients (API) CDMO Basic Information
Table 85. Catalent Active Pharmaceutical Ingredients (API) CDMO Product Overview
Table 86. Catalent Active Pharmaceutical Ingredients (API) CDMO Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 87. Catalent Business Overview
Table 88. Catalent Recent Developments
Table 89. Boehringer Ingelheim Active Pharmaceutical Ingredients (API) CDMO Basic Information
Table 90. Boehringer Ingelheim Active Pharmaceutical Ingredients (API) CDMO Product Overview
Table 91. Boehringer Ingelheim Active Pharmaceutical Ingredients (API) CDMO Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 92. Boehringer Ingelheim Business Overview
Table 93. Boehringer Ingelheim Recent Developments
Table 94. Piramal Group Active Pharmaceutical Ingredients (API) CDMO Basic Information
Table 95. Piramal Group Active Pharmaceutical Ingredients (API) CDMO Product Overview
Table 96. Piramal Group Active Pharmaceutical Ingredients (API) CDMO Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 97. Piramal Group Business Overview
Table 98. Piramal Group Recent Developments
Table 99. AbbVie Active Pharmaceutical Ingredients (API) CDMO Basic Information
Table 100. AbbVie Active Pharmaceutical Ingredients (API) CDMO Product Overview
Table 101. AbbVie Active Pharmaceutical Ingredients (API) CDMO Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 102. AbbVie Business Overview
Table 103. AbbVie Recent Developments
Table 104. SGS Quay Pharmaceuticals Active Pharmaceutical Ingredients (API) CDMO Basic Information
Table 105. SGS Quay Pharmaceuticals Active Pharmaceutical Ingredients (API) CDMO Product Overview
Table 106. SGS Quay Pharmaceuticals Active Pharmaceutical Ingredients (API) CDMO Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 107. SGS Quay Pharmaceuticals Business Overview
Table 108. SGS Quay Pharmaceuticals Recent Developments
Table 109. Aenova Group Active Pharmaceutical Ingredients (API) CDMO Basic Information
Table 110. Aenova Group Active Pharmaceutical Ingredients (API) CDMO Product Overview
Table 111. Aenova Group Active Pharmaceutical Ingredients (API) CDMO Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 112. Aenova Group Business Overview
Table 113. Aenova Group Recent Developments
Table 114. Curia Active Pharmaceutical Ingredients (API) CDMO Basic Information
Table 115. Curia Active Pharmaceutical Ingredients (API) CDMO Product Overview
Table 116. Curia Active Pharmaceutical Ingredients (API) CDMO Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 117. Curia Business Overview
Table 118. Curia Recent Developments
Table 119. Sterling Pharma Solutions Active Pharmaceutical Ingredients (API) CDMO Basic Information
Table 120. Sterling Pharma Solutions Active Pharmaceutical Ingredients (API) CDMO Product Overview
Table 121. Sterling Pharma Solutions Active Pharmaceutical Ingredients (API) CDMO Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 122. Sterling Pharma Solutions Business Overview
Table 123. Sterling Pharma Solutions Recent Developments
Table 124. Eurofins CDMO Active Pharmaceutical Ingredients (API) CDMO Basic Information
Table 125. Eurofins CDMO Active Pharmaceutical Ingredients (API) CDMO Product Overview
Table 126. Eurofins CDMO Active Pharmaceutical Ingredients (API) CDMO Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 127. Eurofins CDMO Business Overview
Table 128. Eurofins CDMO Recent Developments
Table 129. Global Active Pharmaceutical Ingredients (API) CDMO Sales Forecast by Region (2025-2032) & (K Units)
Table 130. Global Active Pharmaceutical Ingredients (API) CDMO Market Size Forecast by Region (2025-2032) & (M USD)
Table 131. North America Active Pharmaceutical Ingredients (API) CDMO Sales Forecast by Country (2025-2032) & (K Units)
Table 132. North America Active Pharmaceutical Ingredients (API) CDMO Market Size Forecast by Country (2025-2032) & (M USD)
Table 133. Europe Active Pharmaceutical Ingredients (API) CDMO Sales Forecast by Country (2025-2032) & (K Units)
Table 134. Europe Active Pharmaceutical Ingredients (API) CDMO Market Size Forecast by Country (2025-2032) & (M USD)
Table 135. Asia Pacific Active Pharmaceutical Ingredients (API) CDMO Sales Forecast by Region (2025-2032) & (K Units)
Table 136. Asia Pacific Active Pharmaceutical Ingredients (API) CDMO Market Size Forecast by Region (2025-2032) & (M USD)
Table 137. South America Active Pharmaceutical Ingredients (API) CDMO Sales Forecast by Country (2025-2032) & (K Units)
Table 138. South America Active Pharmaceutical Ingredients (API) CDMO Market Size Forecast by Country (2025-2032) & (M USD)
Table 139. Middle East and Africa Active Pharmaceutical Ingredients (API) CDMO Consumption Forecast by Country (2025-2032) & (Units)
Table 140. Middle East and Africa Active Pharmaceutical Ingredients (API) CDMO Market Size Forecast by Country (2025-2032) & (M USD)
Table 141. Global Active Pharmaceutical Ingredients (API) CDMO Sales Forecast by Type (2025-2032) & (K Units)
Table 142. Global Active Pharmaceutical Ingredients (API) CDMO Market Size Forecast by Type (2025-2032) & (M USD)
Table 143. Global Active Pharmaceutical Ingredients (API) CDMO Price Forecast by Type (2025-2032) & (USD/Unit)
Table 144. Global Active Pharmaceutical Ingredients (API) CDMO Sales (K Units) Forecast by Application (2025-2032)
Table 145. Global Active Pharmaceutical Ingredients (API) CDMO Market Size Forecast by Application (2025-2032) & (M USD)
LIST OF FIGURES
Figure 1. Product Picture of Active Pharmaceutical Ingredients (API) CDMO
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Active Pharmaceutical Ingredients (API) CDMO Market Size (M USD), 2019-2032
Figure 5. Global Active Pharmaceutical Ingredients (API) CDMO Market Size (M USD) (2019-2032)
Figure 6. Global Active Pharmaceutical Ingredients (API) CDMO Sales (K Units) & (2019-2032)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Active Pharmaceutical Ingredients (API) CDMO Market Size by Country (M USD)
Figure 11. Active Pharmaceutical Ingredients (API) CDMO Sales Share by Manufacturers in 2023
Figure 12. Global Active Pharmaceutical Ingredients (API) CDMO Revenue Share by Manufacturers in 2023
Figure 13. Active Pharmaceutical Ingredients (API) CDMO Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Active Pharmaceutical Ingredients (API) CDMO Average Price (USD/Unit) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Active Pharmaceutical Ingredients (API) CDMO Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Active Pharmaceutical Ingredients (API) CDMO Market Share by Type
Figure 18. Sales Market Share of Active Pharmaceutical Ingredients (API) CDMO by Type (2019-2024)
Figure 19. Sales Market Share of Active Pharmaceutical Ingredients (API) CDMO by Type in 2023
Figure 20. Market Size Share of Active Pharmaceutical Ingredients (API) CDMO by Type (2019-2024)
Figure 21. Market Size Market Share of Active Pharmaceutical Ingredients (API) CDMO by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Active Pharmaceutical Ingredients (API) CDMO Market Share by Application
Figure 24. Global Active Pharmaceutical Ingredients (API) CDMO Sales Market Share by Application (2019-2024)
Figure 25. Global Active Pharmaceutical Ingredients (API) CDMO Sales Market Share by Application in 2023
Figure 26. Global Active Pharmaceutical Ingredients (API) CDMO Market Share by Application (2019-2024)
Figure 27. Global Active Pharmaceutical Ingredients (API) CDMO Market Share by Application in 2023
Figure 28. Global Active Pharmaceutical Ingredients (API) CDMO Sales Growth Rate by Application (2019-2024)
Figure 29. Global Active Pharmaceutical Ingredients (API) CDMO Sales Market Share by Region (2019-2024)
Figure 30. North America Active Pharmaceutical Ingredients (API) CDMO Sales and Growth Rate (2019-2024) & (K Units)
Figure 31. North America Active Pharmaceutical Ingredients (API) CDMO Sales Market Share by Country in 2023
Figure 32. U.S. Active Pharmaceutical Ingredients (API) CDMO Sales and Growth Rate (2019-2024) & (K Units)
Figure 33. Canada Active Pharmaceutical Ingredients (API) CDMO Sales (K Units) and Growth Rate (2019-2024)
Figure 34. Mexico Active Pharmaceutical Ingredients (API) CDMO Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe Active Pharmaceutical Ingredients (API) CDMO Sales and Growth Rate (2019-2024) & (K Units)
Figure 36. Europe Active Pharmaceutical Ingredients (API) CDMO Sales Market Share by Country in 2023
Figure 37. Germany Active Pharmaceutical Ingredients (API) CDMO Sales and Growth Rate (2019-2024) & (K Units)
Figure 38. France Active Pharmaceutical Ingredients (API) CDMO Sales and Growth Rate (2019-2024) & (K Units)
Figure 39. U.K. Active Pharmaceutical Ingredients (API) CDMO Sales and Growth Rate (2019-2024) & (K Units)
Figure 40. Italy Active Pharmaceutical Ingredients (API) CDMO Sales and Growth Rate (2019-2024) & (K Units)
Figure 41. Russia Active Pharmaceutical Ingredients (API) CDMO Sales and Growth Rate (2019-2024) & (K Units)
Figure 42. Asia Pacific Active Pharmaceutical Ingredients (API) CDMO Sales and Growth Rate (K Units)
Figure 43. Asia Pacific Active Pharmaceutical Ingredients (API) CDMO Sales Market Share by Region in 2023
Figure 44. China Active Pharmaceutical Ingredients (API) CDMO Sales and Growth Rate (2019-2024) & (K Units)
Figure 45. Japan Active Pharmaceutical Ingredients (API) CDMO Sales and Growth Rate (2019-2024) & (K Units)
Figure 46. South Korea Active Pharmaceutical Ingredients (API) CDMO Sales and Growth Rate (2019-2024) & (K Units)
Figure 47. India Active Pharmaceutical Ingredients (API) CDMO Sales and Growth Rate (2019-2024) & (K Units)
Figure 48. Southeast Asia Active Pharmaceutical Ingredients (API) CDMO Sales and Growth Rate (2019-2024) & (K Units)
Figure 49. South America Active Pharmaceutical Ingredients (API) CDMO Sales and Growth Rate (K Units)
Figure 50. South America Active Pharmaceutical Ingredients (API) CDMO Sales Market Share by Country in 2023
Figure 51. Brazil Active Pharmaceutical Ingredients (API) CDMO Sales and Growth Rate (2019-2024) & (K Units)
Figure 52. Argentina Active Pharmaceutical Ingredients (API) CDMO Sales and Growth Rate (2019-2024) & (K Units)
Figure 53. Columbia Active Pharmaceutical Ingredients (API) CDMO Sales and Growth Rate (2019-2024) & (K Units)
Figure 54. Middle East and Africa Active Pharmaceutical Ingredients (API) CDMO Sales and Growth Rate (K Units)
Figure 55. Middle East and Africa Active Pharmaceutical Ingredients (API) CDMO Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Active Pharmaceutical Ingredients (API) CDMO Sales and Growth Rate (2019-2024) & (K Units)
Figure 57. UAE Active Pharmaceutical Ingredients (API) CDMO Sales and Growth Rate (2019-2024) & (K Units)
Figure 58. Egypt Active Pharmaceutical Ingredients (API) CDMO Sales and Growth Rate (2019-2024) & (K Units)
Figure 59. Nigeria Active Pharmaceutical Ingredients (API) CDMO Sales and Growth Rate (2019-2024) & (K Units)
Figure 60. South Africa Active Pharmaceutical Ingredients (API) CDMO Sales and Growth Rate (2019-2024) & (K Units)
Figure 61. Global Active Pharmaceutical Ingredients (API) CDMO Production Market Share by Region (2019-2024)
Figure 62. North America Active Pharmaceutical Ingredients (API) CDMO Production (K Units) Growth Rate (2019-2024)
Figure 63. Europe Active Pharmaceutical Ingredients (API) CDMO Production (K Units) Growth Rate (2019-2024)
Figure 64. Japan Active Pharmaceutical Ingredients (API) CDMO Production (K Units) Growth Rate (2019-2024)
Figure 65. China Active Pharmaceutical Ingredients (API) CDMO Production (K Units) Growth Rate (2019-2024)
Figure 66. Global Active Pharmaceutical Ingredients (API) CDMO Sales Forecast by Volume (2019-2032) & (K Units)
Figure 67. Global Active Pharmaceutical Ingredients (API) CDMO Market Size Forecast by Value (2019-2032) & (M USD)
Figure 68. Global Active Pharmaceutical Ingredients (API) CDMO Sales Market Share Forecast by Type (2025-2032)
Figure 69. Global Active Pharmaceutical Ingredients (API) CDMO Market Share Forecast by Type (2025-2032)
Figure 70. Global Active Pharmaceutical Ingredients (API) CDMO Sales Forecast by Application (2025-2032)
Figure 71. Global Active Pharmaceutical Ingredients (API) CDMO Market Share Forecast by Application (2025-2032)
Figure 1. Product Picture of Active Pharmaceutical Ingredients (API) CDMO
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Active Pharmaceutical Ingredients (API) CDMO Market Size (M USD), 2019-2032
Figure 5. Global Active Pharmaceutical Ingredients (API) CDMO Market Size (M USD) (2019-2032)
Figure 6. Global Active Pharmaceutical Ingredients (API) CDMO Sales (K Units) & (2019-2032)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Active Pharmaceutical Ingredients (API) CDMO Market Size by Country (M USD)
Figure 11. Active Pharmaceutical Ingredients (API) CDMO Sales Share by Manufacturers in 2023
Figure 12. Global Active Pharmaceutical Ingredients (API) CDMO Revenue Share by Manufacturers in 2023
Figure 13. Active Pharmaceutical Ingredients (API) CDMO Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Active Pharmaceutical Ingredients (API) CDMO Average Price (USD/Unit) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Active Pharmaceutical Ingredients (API) CDMO Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Active Pharmaceutical Ingredients (API) CDMO Market Share by Type
Figure 18. Sales Market Share of Active Pharmaceutical Ingredients (API) CDMO by Type (2019-2024)
Figure 19. Sales Market Share of Active Pharmaceutical Ingredients (API) CDMO by Type in 2023
Figure 20. Market Size Share of Active Pharmaceutical Ingredients (API) CDMO by Type (2019-2024)
Figure 21. Market Size Market Share of Active Pharmaceutical Ingredients (API) CDMO by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Active Pharmaceutical Ingredients (API) CDMO Market Share by Application
Figure 24. Global Active Pharmaceutical Ingredients (API) CDMO Sales Market Share by Application (2019-2024)
Figure 25. Global Active Pharmaceutical Ingredients (API) CDMO Sales Market Share by Application in 2023
Figure 26. Global Active Pharmaceutical Ingredients (API) CDMO Market Share by Application (2019-2024)
Figure 27. Global Active Pharmaceutical Ingredients (API) CDMO Market Share by Application in 2023
Figure 28. Global Active Pharmaceutical Ingredients (API) CDMO Sales Growth Rate by Application (2019-2024)
Figure 29. Global Active Pharmaceutical Ingredients (API) CDMO Sales Market Share by Region (2019-2024)
Figure 30. North America Active Pharmaceutical Ingredients (API) CDMO Sales and Growth Rate (2019-2024) & (K Units)
Figure 31. North America Active Pharmaceutical Ingredients (API) CDMO Sales Market Share by Country in 2023
Figure 32. U.S. Active Pharmaceutical Ingredients (API) CDMO Sales and Growth Rate (2019-2024) & (K Units)
Figure 33. Canada Active Pharmaceutical Ingredients (API) CDMO Sales (K Units) and Growth Rate (2019-2024)
Figure 34. Mexico Active Pharmaceutical Ingredients (API) CDMO Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe Active Pharmaceutical Ingredients (API) CDMO Sales and Growth Rate (2019-2024) & (K Units)
Figure 36. Europe Active Pharmaceutical Ingredients (API) CDMO Sales Market Share by Country in 2023
Figure 37. Germany Active Pharmaceutical Ingredients (API) CDMO Sales and Growth Rate (2019-2024) & (K Units)
Figure 38. France Active Pharmaceutical Ingredients (API) CDMO Sales and Growth Rate (2019-2024) & (K Units)
Figure 39. U.K. Active Pharmaceutical Ingredients (API) CDMO Sales and Growth Rate (2019-2024) & (K Units)
Figure 40. Italy Active Pharmaceutical Ingredients (API) CDMO Sales and Growth Rate (2019-2024) & (K Units)
Figure 41. Russia Active Pharmaceutical Ingredients (API) CDMO Sales and Growth Rate (2019-2024) & (K Units)
Figure 42. Asia Pacific Active Pharmaceutical Ingredients (API) CDMO Sales and Growth Rate (K Units)
Figure 43. Asia Pacific Active Pharmaceutical Ingredients (API) CDMO Sales Market Share by Region in 2023
Figure 44. China Active Pharmaceutical Ingredients (API) CDMO Sales and Growth Rate (2019-2024) & (K Units)
Figure 45. Japan Active Pharmaceutical Ingredients (API) CDMO Sales and Growth Rate (2019-2024) & (K Units)
Figure 46. South Korea Active Pharmaceutical Ingredients (API) CDMO Sales and Growth Rate (2019-2024) & (K Units)
Figure 47. India Active Pharmaceutical Ingredients (API) CDMO Sales and Growth Rate (2019-2024) & (K Units)
Figure 48. Southeast Asia Active Pharmaceutical Ingredients (API) CDMO Sales and Growth Rate (2019-2024) & (K Units)
Figure 49. South America Active Pharmaceutical Ingredients (API) CDMO Sales and Growth Rate (K Units)
Figure 50. South America Active Pharmaceutical Ingredients (API) CDMO Sales Market Share by Country in 2023
Figure 51. Brazil Active Pharmaceutical Ingredients (API) CDMO Sales and Growth Rate (2019-2024) & (K Units)
Figure 52. Argentina Active Pharmaceutical Ingredients (API) CDMO Sales and Growth Rate (2019-2024) & (K Units)
Figure 53. Columbia Active Pharmaceutical Ingredients (API) CDMO Sales and Growth Rate (2019-2024) & (K Units)
Figure 54. Middle East and Africa Active Pharmaceutical Ingredients (API) CDMO Sales and Growth Rate (K Units)
Figure 55. Middle East and Africa Active Pharmaceutical Ingredients (API) CDMO Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Active Pharmaceutical Ingredients (API) CDMO Sales and Growth Rate (2019-2024) & (K Units)
Figure 57. UAE Active Pharmaceutical Ingredients (API) CDMO Sales and Growth Rate (2019-2024) & (K Units)
Figure 58. Egypt Active Pharmaceutical Ingredients (API) CDMO Sales and Growth Rate (2019-2024) & (K Units)
Figure 59. Nigeria Active Pharmaceutical Ingredients (API) CDMO Sales and Growth Rate (2019-2024) & (K Units)
Figure 60. South Africa Active Pharmaceutical Ingredients (API) CDMO Sales and Growth Rate (2019-2024) & (K Units)
Figure 61. Global Active Pharmaceutical Ingredients (API) CDMO Production Market Share by Region (2019-2024)
Figure 62. North America Active Pharmaceutical Ingredients (API) CDMO Production (K Units) Growth Rate (2019-2024)
Figure 63. Europe Active Pharmaceutical Ingredients (API) CDMO Production (K Units) Growth Rate (2019-2024)
Figure 64. Japan Active Pharmaceutical Ingredients (API) CDMO Production (K Units) Growth Rate (2019-2024)
Figure 65. China Active Pharmaceutical Ingredients (API) CDMO Production (K Units) Growth Rate (2019-2024)
Figure 66. Global Active Pharmaceutical Ingredients (API) CDMO Sales Forecast by Volume (2019-2032) & (K Units)
Figure 67. Global Active Pharmaceutical Ingredients (API) CDMO Market Size Forecast by Value (2019-2032) & (M USD)
Figure 68. Global Active Pharmaceutical Ingredients (API) CDMO Sales Market Share Forecast by Type (2025-2032)
Figure 69. Global Active Pharmaceutical Ingredients (API) CDMO Market Share Forecast by Type (2025-2032)
Figure 70. Global Active Pharmaceutical Ingredients (API) CDMO Sales Forecast by Application (2025-2032)
Figure 71. Global Active Pharmaceutical Ingredients (API) CDMO Market Share Forecast by Application (2025-2032)
